Instil Bio, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
TIL$6.35-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended | ||
|---|---|---|
| September 30, | ||
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(63,181) | $(62,240) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 7,087 | 12,756 |
| Non-cash lease expense | 214 | 174 |
| Foreign exchange remeasurement gain | (503) | (278) |
| Impairment of property, plant and equipment | 16,569 | 4,285 |
| Impairment of right-of-use assets | — | 827 |
| Change in fair value of contingent consideration | — | (2,500) |
| Depreciation | 522 | 2,869 |
| Restructuring costs | (91) | — |
| In-process research and development expenses | 10,000 | 10,000 |
| Accretion on invested securities | (70) | (3,861) |
| Non-cash interest expense | 598 | 754 |
| Change in fair value of derivative financial instrument | — | 265 |
| Loss on disposals of property and equipment | — | 343 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 4,933 | (2,540) |
| Other long-term assets | 345 | (3,115) |
| Accrued rent receivable | (3,093) | (1,493) |
| Accounts payable | 264 | (34) |
| Operating lease liabilities | (1,561) | (995) |
| Accrued expenses and other current liabilities | (1,576) | (354) |
| Net cash used in operating activities | (29,543) | (45,137) |
| Cash flows from investing activities: | ||
| Purchase of marketable securities | (83,465) | (106,684) |
| Maturities of marketable securities | 110,700 | 158,700 |
| Cash received from held for sale assets | 423 | 546 |
| Acquired in-process research and development | (10,000) | (10,000) |
| Purchase of derivative financial instrument | — | (1,588) |
| Net cash provided by investing activities | 17,658 | 40,974 |
| Cash flows from financing activities: | ||
| Proceeds from at-the-market offering, net of $0.3 million in issuance costs | 6,611 | — |
| Proceeds from exercise of stock options | 853 | 159 |
| Loan agreement closing costs | (172) | — |
| Net cash provided by financing activities | 7,292 | 159 |
| Net decrease in cash, cash equivalents and restricted cash | (4,593) | (4,004) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 39 | (29) |
| Cash, cash equivalents and restricted cash—beginning of period | 10,635 | 10,696 |
| Cash, cash equivalents and restricted cash—end of period | $6,081 | $6,663 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $3,664 | $5,241 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.